K36 Therapeutics

• locale

  United States

• market

  PRIVATE

• industry

  Biotechnology

• website

  www.k36tx.com

K36 Therapeutics is a biopharmaceutical company focused on developing targeted therapies for multiple myeloma patients. Their lead candidate, KTX-1001, is a selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in some multiple myeloma patients due to a specific genetic translocation.